Filing Flows › Comparisons › GSK vs JNJ
GSK vs Johnson & Johnson: GSK and JNJ compared
GSK is the larger company: $32.7B of revenue in its latest quarter (FY2025) against $25.4B for Johnson & Johnson (Q3 2026). Johnson & Johnson is growing faster (+6% against +4% a year earlier). GSK is more profitable, with an operating margin of 24.3% against 0.1%.
Where the money goes: GSK and JNJ
GSK (GSK) · FY2025
GSK, FY2025: revenue $32.7B (+4% year over year), operating margin 24.3%, net earnings $5.7B, operating cash flow $7.7B. The chart follows the revenue to costs, profit and cash.
Johnson & Johnson (JNJ) · Q3 2026
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart follows the revenue to costs, profit and cash.
| GSK (GSK) | Johnson & Johnson (JNJ) | |
|---|---|---|
| Latest quarter | FY2025 | Q3 2026 |
| Revenue | $32.7B | $25.4B |
| Revenue growth, Y/Y | +4% | +6% |
| Gross margin | 72.4% | 68.1% |
| Operating margin | 24.3% | 0.1% |
| Net earnings | $5.7B | $210M |
| Net margin | 17.5% | 0.8% |
| Operating cash flow | $7.7B | $7.7B |
| Free cash flow | $6.4B | $6.4B |
| Market value | $217.2B | $676.4B |
| P/E | 34.5× | 42.0× |
| Analysts’ mean target | $59.12 | $279.41 |
Where the revenue comes from
Johnson & Johnson
- Innovative Medicine: $16.8B (66%)
- MEDTECH: $8.6B (34%)
Questions
Which is bigger, GSK or Johnson & Johnson?
GSK is the larger company: $32.7B of revenue in its latest quarter (FY2025) against $25.4B for Johnson & Johnson (Q3 2026).
Is GSK or Johnson & Johnson growing faster?
Johnson & Johnson is growing faster (+6% against +4% a year earlier).
Which is more profitable, GSK or Johnson & Johnson?
GSK is more profitable, with an operating margin of 24.3% against 0.1%.
More: GSK earnings · how GSK makes money · Johnson & Johnson earnings · how Johnson & Johnson makes money
From the companies' latest 10-Q, 10-K or earnings release (20-F filed Mar 6, 2026; 10-Q filed Oct 21, 2026). Fiscal quarters can end on different dates. Not investment advice.